British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK
British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK.
Heart. 2023 Oct 26;109(22):1677-1682. doi: 10.1136/heartjnl-2023-322514.
In patients with abdominal aortic aneurysms, sodium [F]fluoride positron emission tomography identifies aortic microcalcification and disease activity. Increased uptake is associated with aneurysm expansion and adverse clinical events. The effect of endovascular aneurysm repair (EVAR) on aortic disease activity and sodium [F]fluoride uptake is unknown. This study aimed to compare aortic sodium [F]fluoride uptake before and after treatment with EVAR.
In a preliminary proof-of-concept cohort study, preoperative and post-operative sodium [F]fluoride positron emission tomography-computed tomography angiography was performed in patients with an infrarenal abdominal aortic aneurysm undergoing EVAR according to current guideline-directed size treatment thresholds. Regional aortic sodium [F]fluoride uptake was assessed using aortic microcalcification activity (AMA): a summary measure of mean aortic sodium [F]fluoride uptake.
Ten participants were recruited (76±6 years) with a mean aortic diameter of 57±2 mm at time of EVAR. Mean time from EVAR to repeat scan was 62±21 months. Prior to EVAR, there was higher abdominal aortic AMA when compared with the thoracic aorta (AMA 1.88 vs 1.2; p<0.001). Following EVAR, sodium [F]fluoride uptake was markedly reduced in the suprarenal (ΔAMA 0.62, p=0.03), neck (ΔAMA 0.72, p=0.02) and body of the aneurysm (ΔAMA 0.69, p=0.02) while it remained unchanged in the thoracic aorta (ΔAMA 0.11, p=0.41).
EVAR is associated with a reduction in AMA within the stented aortic segment. This suggests that EVAR can modify aortic disease activity and aortic sodium [F]fluoride uptake is a promising non-invasive surrogate measure of aneurysm disease activity.
在患有腹主动脉瘤的患者中,[F]氟酸钠正电子发射断层扫描可识别主动脉微钙化和疾病活动。摄取增加与动脉瘤扩张和不良临床事件相关。血管内动脉瘤修复术(EVAR)对主动脉疾病活动和[F]氟酸钠摄取的影响尚不清楚。本研究旨在比较 EVAR 前后主动脉[F]氟酸钠摄取。
在初步的概念验证队列研究中,根据当前指南指导的大小治疗阈值,对接受 EVAR 的肾下腹部主动脉瘤患者进行术前和术后[F]氟酸钠正电子发射断层扫描-计算机断层血管造影术。使用主动脉微钙化活性(AMA)评估区域性主动脉[F]氟酸钠摄取:一种平均主动脉[F]氟酸钠摄取的综合测量指标。
共招募了 10 名参与者(76±6 岁),EVAR 时的平均主动脉直径为 57±2 mm。从 EVAR 到重复扫描的平均时间为 62±21 个月。在 EVAR 之前,与胸主动脉相比,腹主动脉的 AMA 更高(AMA 1.88 比 1.2;p<0.001)。在 EVAR 之后,肾上(ΔAMA 0.62,p=0.03)、颈部(ΔAMA 0.72,p=0.02)和动脉瘤体(ΔAMA 0.69,p=0.02)的[F]氟酸钠摄取明显减少,而胸主动脉的[F]氟酸钠摄取没有变化(ΔAMA 0.11,p=0.41)。
EVAR 与支架主动脉段内 AMA 的减少相关。这表明 EVAR 可以改变主动脉疾病活动,并且主动脉[F]氟酸钠摄取是动脉瘤疾病活动的有前途的非侵入性替代测量指标。